Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair (EVAR_DAPT_SAPT)

Samsung Medical Center

Status: Completed

Conditions: Endovascular Aneurysm Repair (EVAR); Abdominal Aortic Aneurysms (AAA)

Study type: Observational

Funder types: Other

Identifiers

NCT06876727

Antiplatelet After EVAR

Details and patient eligibility

About

This study was a target trial emulation using the National Health Claims database established by the Korean National Health Insurance Service (K-NHIS). 8,325 patients were included.

Full description

Among these patients, any patients who were prescribed SAPT or DAPT at the date of discharge from the index hospitalization for standard EVAR were defined as being in the SAPT group (N=4,162) and the DAPT group (N=4,163), respectively.

Enrollment: 8,325 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients who underwent EVAR for AAA and were successfully discharged

Exclusion criteria

• Patients who had experienced a myocardial infarction
• Patients who had experienced a stroke
• Patients who had experienced percutaneous coronary intervention
• Patients who had history of peripheral disease
• Patients who had major bleeding event within 1 year of admission
• Those prescribed non-vitamin K antagonist oral anticoagulant or warfarin
• Patients who did not prescribe any antiplatelet therapy

Trial design

8,325 participants in 2 patient groups

Dual antiplatelet therapy

Description:

Patients who were prescribed dual antiplatelet therapy at the date of discharge from the index hospitalization for standard EVAR

Single antiplatelet therapy

Description:

Patients who were prescribed single antiplatelet therapy at the date of discharge from the index hospitalization for standard EVAR